Demethylation of CDKN2A in systemic lupus erythematosus and rheumatoid arthritis: a blood biomarker for diagnosis and assessment of disease activity.
Abdollah GravandSamira AlesaeidiShahrouz KhoshbakhtMozhdeh SaghaeiTaiebe KenarangiMeysam MosallaeiMohsen SoosanabadiPublished in: Clinical rheumatology (2023)
Our findings demonstrated that CDKN2A methylation levels in PBMCs of SLE and RA patients could be used as a promising diagnostic biomarker. The significant association between hypomethylation of CDKN2A promoter and disease activity factors in SLE patients, is suggesting that CDKN2A hypomethylation could be used as an alternative biomarker for assessment of disease activity. Key Points • Several studies have reported increased expression of CDKN2A in SLE and RA suggesting that it may be involved in the pathogenesis of these disorders. • CDKN2A hypomethylation has been implicated in different autoimmune diseases. • Our findings demonstrated that CDKN2A methylation levels in PBMCs of SLE and RA patients could be used as a promising diagnostic and prognostic biomarker.
Keyphrases
- disease activity
- rheumatoid arthritis
- systemic lupus erythematosus
- rheumatoid arthritis patients
- ankylosing spondylitis
- end stage renal disease
- juvenile idiopathic arthritis
- chronic kidney disease
- newly diagnosed
- ejection fraction
- dna methylation
- prognostic factors
- peritoneal dialysis
- gene expression
- genome wide
- patient reported outcomes
- long non coding rna
- systemic sclerosis